Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI), focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, has announced its participation in three major investor conferences this March.
The schedule includes:
- TD Cowen 45th Annual Health Care Conference (March 3-5) in Boston, featuring a corporate presentation on March 4 at 10:30 AM ET by CFO Lisa Delfini and CCO Farrell Simon
- Leerink Partners Global Healthcare Conference (March 10-12) in Miami, with a presentation on March 12 at 8:00 AM ET by CEO Jennifer Good and CDO James Cassella
- Leerink Partners Mountain Meeting (March 23-26) in Jackson Hole, with CFO Lisa Delfini representing
All events will feature corporate presentations available to in-person attendees.
Trevi Therapeutics (NASDAQ: TRVI) has completed enrollment in its Phase 2b CORAL trial of Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Topline results are expected in the first half of 2025.
The CORAL trial is evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) against placebo in approximately 160 IPF patients with chronic cough over a 6-week period. The study includes a 2-week titration period followed by 4 weeks of fixed dosing.
The primary endpoint measures the relative change in 24-hour cough frequency at Week 6 versus baseline, using an objective cough monitor. Secondary endpoints include patient-reported outcome measures for cough.
According to James Cassella, Chief Development Officer, chronic cough significantly impacts IPF patients, and current treatments are often ineffective, creating a substantial unmet need. Results will help determine optimal doses for the pivotal Phase 3 program.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences this February. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will be represented by key executives at these events.
The conferences include the Piper Sandler Biopharma Mogul Summit (February 2-4) in Park City, Utah, where CFO Lisa Delfini will attend; the Oppenheimer Healthcare 2025 Winter CEO & Investor Summit (February 3-6) in Vail, Colorado, featuring CEO Jennifer Good; and the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference (February 11-12), where Jennifer Good and Chief Development Officer James Cassella will deliver a corporate presentation on February 11 at 9:20 AM ET.
Trevi Therapeutics (NASDAQ: TRVI) provided key updates on its clinical trials and financial position. The company completed patient visits for its Phase 2a RIVER trial in refractory chronic cough (RCC), with topline results expected in Q1 2025. The Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough is approximately 80% enrolled, with results anticipated in H1 2025.
The company recently announced positive outcomes from both the sample size re-estimation analysis of the Phase 2b CORAL trial and their Human Abuse Potential study. Trevi's preliminary estimate indicates cash, cash equivalents, and marketable securities of $107.6 million as of December 31, 2024, providing runway into H2 2026.
Trevi Therapeutics (TRVI) has announced the pricing of an underwritten offering of 12,500,000 shares of common stock at $4.00 per share, aiming to raise $50 million before deducting underwriting costs. The offering, expected to close on December 17, 2024, includes participation from notable investors such as Adage Capital Partners LP, Frazier Life Sciences, and Vivo Capital.
The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in idiopathic pulmonary fibrosis and refractory chronic cough, is conducting the offering through a shelf registration statement previously filed with the SEC. Leerink Partners, Stifel, and Oppenheimer & Co. are serving as joint book-running managers.
Trevi Therapeutics (NASDAQ: TRVI) announced positive results from its planned sample size re-estimation (SSRE) for the Phase 2b CORAL trial, confirming no changes needed to the current sample size of 160 patients. The trial, testing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) patients, has reached 75% enrollment, with topline results expected in H1 2025.
The SSRE analysis, conducted on the highest dose (108mg twice daily) after 80 patients completed treatment, supported maintaining the pre-specified conditional power of 80% or greater. The CORAL trial is evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) against placebo in IPF patients with chronic cough, with the primary endpoint measuring relative change in 24-hour cough frequency.
Trevi Therapeutics (NASDAQ: TRVI) announced positive results from their human abuse potential (HAP) study of oral nalbuphine. The study demonstrated statistically significant lower 'Drug Liking' for clinical doses (81mg and 162mg) compared to 6mg IV butorphanol. The primary endpoint measured peak effect for 'Drug Liking' on a 100-point visual analog scale.
Key findings showed mean Emax 'Drug Liking' scores of 71.2 and 74.5 for 81mg and 162mg oral nalbuphine respectively, compared to 82.3 for butorphanol (p<0.0001 and p=0.0008). Secondary endpoints were consistent with primary findings. The supratherapeutic dose (486mg) showed numerically lower but not statistically significant results. No serious adverse events were reported.
Trevi Therapeutics (Nasdaq: TRVI) announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3-5 in New York. Jennifer Good, President and CEO, will deliver a corporate presentation on December 4, 2024, at 1:00 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will also have its CEO and CFO participate in investor meetings during the event. The presentation and meetings will be accessible to in-person attendees.
Trevi Therapeutics (Nasdaq: TRVI) announced its third quarter 2024 financial results and business updates.
The company completed enrollment in the Phase 2a RIVER trial for refractory chronic cough (RCC), with topline results expected in Q1 2025. It also reached 50% enrollment in the Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation results due in December 2024.
Trevi ended Q3 2024 with $65.5 million in cash and equivalents, projecting a cash runway into the second half of 2026.
R&D expenses rose to $11.2 million from $6.3 million year-over-year, driven by increased clinical development costs. G&A expenses increased slightly to $2.9 million. The company reported a net loss of $13.2 million, compared to $7.7 million in Q3 2023.
Topline results from the Human Abuse Potential (HAP) study are expected in December 2024.
Trevi Therapeutics (NASDAQ: TRVI) has announced it will report its Q3 2024 financial results and provide a corporate update on November 6, 2024, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will host a conference call and webcast. Participants can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available on the company's website and archived for 30 days.